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has been estimated from clinical trials data. The cost of general practitioner visits,
specialist visits, hospitalizations and emergency department visits were included.
Costs and utility values attached to various health states were taken from the
published literature. RESULTS: Lacosamide adjunctive therapy was associated
with 6,730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs),
compared to the standard therapy armwithin the two-year timeframe. Treatment
with lacosamide was associated with a cost of $223 per seizure avoided, and
$39,574 per QALY gained versus standard therapy over two years and falls within
acceptable thresholds of cost-effectiveness in the United States. Results calculated
for 6-, 12- and 18-month follow-up showed respective incremental cost-utility ra-
tios of $55,465, $46,587 and $44,559 and cost per seizure avoided of $733, $305 and
$260. Using a willingness-to-pay threshold of $50,000 per QALY, 77% of the simu-
lations fell below this value after 2 years of treatment. CONCLUSIONS: Lacosamide
was shown to be a cost-effective adjunctive treatment in patients with uncon-
trolled partial-onset epilepsy in the United States.
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OBJECTIVES: Examinehowchanges in themedication possession ratio (MPR) affect
patient outcomes among multiple sclerosis (MS) patients treated with glatiramer
acetate (GA; Copaxone®). METHODS: Data were obtained from i3 InVision Data
Mart for january 1, 2006 – March 31, 2010. Patients were included if they were
diagnosed with MS, initiated therapy with GA, and had continuous insurance cov-
erage from 6 months prior through 24 months post initial use of GA (N839).
Multivariate regressions which controlled for patient characteristics examined the
association between achievement of alternative MPR goals and patient relapses
and charges. Logistic regressions were used to examine the relapses, while gene-
ralized linear models were used to examine charges. RESULTS: Patients who
achieved an MPR of at least 0.7 had significantly lower odds of relapse, with
achievement of a threshold of 0.7, 0.8 or 0.9, respectively, associated with an odds
ratio of relapse of 0.545 (95% CI 0.351 – 0.824), 0.530 (95% CI 0.371 – 0.870), and 0.421
(95% CI 0.260 – 0.679). Larger reductions in total direct medical charges, excluding
drugs, were seenwith higherMPR thresholds, For example, achievement of anMPR
threshold of at least 0.5 was associated with $1524 lower total charges (P0.0034),
while a MPR threshold of 0.90 was associated with $1825 lower charges (P0.0005).
Examining MS-related total charges, exclusive of drugs, revealed that a MPR
threshold of 0.90 was associated with $986 lower total MS-related charges
(P0.0498). Results also found an association between patient adherence to GA and
statistically significant reduction in inpatient, ER, outpatient, MS-related inpatient
and MS-related outpatient charges. CONCLUSIONS: As adherence improves the
odds of relapse decreases and cost-savings, exclusive of drugs, generally increase.
Results suggest that, despite the higher costs associated with increased usage of
GA, patient outcomes are improved and there are cost-offsets associated with
“compliant” use of the medication.
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OBJECTIVES:Huntington’s disease (HD) is a rare neurodegenerative disease affect-
ingmotor, cognitive and psychological function. Data collection is difficult because
of the low prevalence and the small number of specialized centers. The creation of
a specific self-administered questionnaire covering various clinical aspects of the
disease would make the HD-patient clinical data collection easier. Such an instru-
ment also offers the advantage of allowing a remote follow-up and getting infor-
mation on the development of motor, functional and behavioral disorders of HD
patients perceived by the patient himself. The objective of this study is to validate
a new self-reported clinical instrument for HD-patients.METHODS: The European
HD burden study (Euro-HDB) is an ongoing cross-sectional survey among HD-pa-
tients and their caregivers in six European countries. The H-CSRI, a self-reported
instrument based on the Unified Huntington’s Disease Rating Scale (UHDRS) and
developedwith the expertise of a neurologist and a psychiatrist, was administered.
It included three subscales assessing themotor, functional and behavioural ability.
Classical test theory and item response theory were used to assess its clinimetric
properties. RESULTS: Among 311 patients from both Italy and France, item re-
sponse rates range from 86% to 99%. There was a floor effect on items related to
psychotic disorder in the behavioral subscale, because these symptoms do not
affect all patients. The H-CSRI showed an acceptable reliability (Cronbach’s al-
phas 0.74). Factor analyses demonstrated a satisfactory construct validity. More-
over, the item internal consistency and item discriminant validity criteria were
met. The differential item functioning analyses showed no item bias between the
two countries and between genders. CONCLUSIONS: These data support the valid-
ity of the H-CSRI to assess the health status for patients with HD. Planned next
steps include assessments of responsiveness to change, test–retest reliability and
convergence between UHDRS and H-CSRI scales.
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OBJECTIVES:Migraine in some patients may be progressive, with increasing head-
ache day frequency leading to Chronic Migraine (CM). The relationship between
headache-days per month (HDPM) and health utility, a measure of health-related
quality of life (HRQoL), among patients with migraine has not been examined.
METHODS: The PREEMPT trials studied 1,384 patients with CM treated with
BOTOX® or placebo. The PREEMPT trials included migraine specific measures.
Noo instrument to directly capture health utility, however, was included. There-
fore, a validated mapping algorithm using patient characteristics, the Migraine
Specific Questionnaire v.2 (MSQ), and the EuroQol-5D (EQ-5D, UK weighted) was
applied to the PREEMPT dataset in order to estimate mean health utility by
health state, defined as 0-3, 4-9, 10-14, 15-19, 20-23, or24 HDPM. Analyses were
performed both regardless of treatment and stratified by treatment arm. Health
utility is a standard scale to measure HRQoL, ranging from 1, representing per-
fect health, to 0, representing death. RESULTS: PREEMPT patients were predom-
inantly female (86%) and Caucasian (90%), with amean age of 41. At week 24, mean
health utility for each of the HDPM categorieswas 0.75 (0-3 HDPM), 0.68 (4-9 HDPM),
0.62 (10-14 HDPM), 0.53 (15-19 HDPM), 0.53 (20-23 HDPM), and 0.52 (24 HDPM). A
similar trend of decreasing utility with increasing HDPMwas observed at baseline,
week 12, and week 56 and when stratified by treatment arm. CONCLUSIONS: An
inverse relationship is seen between health utility and HDPM, with the headache
frequency categories comprising CM (15-19, 20-23, and 24HDPM) associated with
the lowest HRQoL. Health utility defined by HDPM categories will be valuable for
estimating HRQoL gains as a result ofmigraine treatmentswhich aim to reduce the
number of HDPM among those suffering from migraine.
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OBJECTIVES: Chronic migraine is an undertreated and debilitating disease associ-
ated with significant morbidity. This research seeks to define meaningful health
states based on published literature and where necessary, expert opinion. Health
states defined by the number of headache-days per month (28 days; HDPM) expe-
rienced by patients with chronic migraine (15 headache days per month) can be
used to calculate transition probabilities that may be applied to cost-effectiveness
modeling. METHODS: Published literature, headache treatment guidelines,
heath utility, and health resource utilization, as well as the baseline distribution
of HDPM in the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Ther-
apy (PREEMPT) clinical trial program were considered to ascertain relevant HDPM
to define migraine health states. Subsequently, pooled trial data were used to
estimate transitions between health states per 12-week treatment cycle for pa-
tients treated with BOTOX® or placebo. Up to 24 weeks of double-blind data is
available from the PREEMPT phase 3 trials, with an additional 32 weeks of open-
label data for BOTOX® treated patients. All available data from the PREEMPT trials
were used to model transitions. A Bayesian approach with a Dirichlet distribution
was used to perform sensitivity analyses of these health state transitions.
RESULTS: We specified 6 unique health states, defined by number of HDPM: 0-3,
4-9, 10-14, 15-19, 20-23, and 24. The pooled trial cohort of 1384 patients (857 with
prior prophylaxis failure) were examined at baseline, week 12 and week 24 to
produce transition probabilities for both all patients and those with prior prophy-
lactic failure. Estimated transition probabilities modeled to one year time horizon
produce distributions that closely replicate the 56-week distribution of the PRE-
EMPT trial population. CONCLUSIONS: This research generated unique migraine
health states to form the foundation of cost-effectiveness models evaluating mi-
graine therapies.
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OBJECTIVES: Migraine is a debilitating disease with significant morbidity. This
research estimates the health resource utilization and associated cost of adult
Scottish migraneurs within 6 distinct health states, defined by number of head-
ache-days per month (28 days; HDPM), ranging from zero to 28, to inform a cost-
effectiveness analysis of prophylaxis of headache in patients with chronic mi-
graine (15 HDPM). METHODS: Standard cost of illness methods were used to
combine unit costs for physician office visits, inpatient and emergency room en-
counters for migraine, and triptan medication use. Resource utilization data was
taken from the International Burden of Migraine Study. Costs were derived from
the NHS 2008/09 reference costs for England, and from the Personal Social Services
Research Unit (PSSRU) costs. Total costs for each health state were estimated over
a three month time interval. RESULTS: Resource utilization increased across all
categories as the number of HDPM increased. Costs per 3 months ranged from
£35.05 for the 0-3 headache-days health state to £226.14 for the 15 HDPM
health state. The largest cost driver among the 15 HDPM was hospitalization
for migraine, which accounted for 52% of costs in 15 HDPM health state.
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CONCLUSIONS: Resource utilization and costs associated with migraine increased
with greater headache frequency. Treatments that reduce headache frequency
have the potential to have a positive economic impact by reducing costs associated
with migraine care.
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OBJECTIVES: To conduct a pilot study examining the validity and reliability of a
paper-based standard gamble (PSG) instrument and to administer the validated
PSG among persons with hemophilia B enrolled in the Hemophilia Utilization
Group Study (HUGS-Vb). METHODS: Fifteen pharmacy students were enrolled in
this pilot. We presented a hypothetical scenario describing a patient with severe
hemophilia to each participant, followed by three tests: (1)Standard Gamble (SG)
using the probability wheel, (2)PSG and (3)Visual Analog Scale (VAS), each admin-
istered in random order. PSG was re-administered after two weeks to assess test-
retest reliability. The validated PSGwas subsequently administered to participants
enrolled in HUGS-Vb, a prospective, multicenter study collecting utilization and
other data associated with hemophilia B in the United States. Participants or their
parent(s) completed a demographic questionnaire, the PSG and the EQ-5D. A PSG
scenario based on actual demographic and clinical characteristics was created for
each participant. Paired t-test, Spearman rank correlation coefficient (rho) and
intra-class correlation coefficient (ICC) were used to assess the convergent validity
and reliability of the instrument. RESULTS:Mean SG, PSG and VAS in the pilot were
0.790.15, 0.820.14 and 66.823.0, respectively. The mean difference between
PSG and SG did not differ significantly from 0 (p0.124). PSG was significantly
correlated with SG (rho0.769, p0.0008) and VAS (rho0.534, p0.0405). PSG re-
test score was 0.790.13 and test-retest ICC was 0.85 (95% CI: 0.63-0.94; p0.0001).
Of 71 HUGS-Vb participants, 32 (45%) were adults; 38 (54%) had severe hemophilia.
Mean agewas 21.8 years (range 2-61). Mean PSG andVAS scoreswere 0.910.15 and
84.414.6 respectively, with weak correlation between the two (rho0.242,
p0.0452) in the full sample. Adult PSG and EQ-5D scores were 0.870.18 and
0.850.16 respectively, with correlation rho0.348 (p0.0506). CONCLUSIONS: A
paper-based standard gamble instrument may be a valid, reliable alternative to SG
for measuring health utility in hemophilia patients.
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OBJECTIVES: To map the Insomnia Severity Index (ISI) to the EQ-5D utilities.
METHODS: A cross-sectional, online survey was conducted among adult US resi-
dents with self-reported sleep problems. Respondents provided demographic, co-
morbidity, previous-night sleep-related information and, completed the EQ-5Dand
the ISI, a seven-item instrument measuring perceived insomnia severity. Each ISI
item is scored from 0-4 with minimum total score of 0 (no insomnia) and a maxi-
mum of 28 (most severe insomnia). Respondents can be classified into four ISI
categories (0-7: no clinically significant insomnia; 8-14 subthreshold insomnia; 15-
21: moderate insomnia; 22-28: severe insomnia). Generalized linear models were
used to map the seven ISI items (Model 1), the ISI summary scores (Model 2), and
the four ISI clinical categories (Model 3) onto EQ-5D utilities. Predictions were esti-
mated using 50/50 split sample validation. Model fits were assessed using mean
squared error (MSE) and distributional quality of predicted values. RESULTS: Re-
spondents (n2,842) were predominantly middle-aged, female, Caucasian, with
1 comorbidity. Mean sleep duration was 7.8 (1.9) hours, mean ISI score was 14.1
(4.8). Mean predicted utilities were (0.7650.08) across all models, overlapping
with observed utilities (0.7650.18). Using Model 1, predicted utilities increased
linearly with improving ISI (0.493 if ISI28; 1.00 if ISI0, p0.01). In Model 2, each
unit decrease in ISI summary was associated with a 0.022 (p0.001) increase in
utility. Predicted utilities were 0.868, 0.809, 0.722 and 0.579 for no clinical, sub-
threshold, moderate and severe insomnia, respectively (Model 3). The overall MSEs
betweenpredictedandobservedutilitiesweregood inallmodels (Model I: 0.025,Model
II & III: 0.026), especiallywhenpredicting utilities0.40 (MSEs: 0.016-0.056).MSEswere
higher when predicting lower utilities (MSEs: 0.138-0.156). CONCLUSIONS: Linear re-
lationshipswere found between EQ-5Dutilities and the ISI. These relationships can
be used to estimate the impact of insomnia-associated treatment effects on utili-
ties.
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OBJECTIVES: To create and implement a secure web-based research program
that collects and tracks validated patient-reported outcomes (PROs) for multiple
sclerosis (MS) patients and their healthcare providers (HCP).METHODS: The My
MS Health program can be accessed through a HIPAA secure website, www.
mymshealth.org. A pilot study to evaluate the My MS Health program has been
IRB-approved. Assessment of inclusion/exclusion criteria, enrollment, and in-
formed consent with an electronic signature occurs through this secure web-
site. Enrolled patients are prompted to complete a series of nine validated PRO
surveys that measure MS specific symptom status, functional status, and qual-
ity-of-life, and results are immediately available. Patients may elect to give their
HCP access to their real-time PRO results electronically. Aggregate data analysis
can also be performed on the collected PRO data. RESULTS: In this ongoing study,
927 patients were enrolled and 122 were eligible to participate in the program
evaluation survey at three months. Scores were measured on 5-point Likert scales
with a range of low agreement (1) to high agreement (5) and scores greater than or
equal to 3 signify agreement. Overall, 93% felt the amount of time it took to answer
the surveys was just right, and 91% felt the website was easy to use (4.51.05). In
addition, 92% reported they would likely continue participating in the program
(4.081.11) and 78% reported they would likely recommendMyMS Health to others
(3.851.48). CONCLUSIONS: Preliminary results indicate My MS Health is an effi-
cient and user friendly technology platform that patients will continue to use.
Future evaluations will assess the impact of using the program on patient and HCP
communication.
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OBJECTIVES: To assess the relationship between internal locus of control (ILOC)
and treatment satisfaction in MS patients after 1 year of natalizumab treatment.
METHODS: MS patients completed the Treatment Satisfaction Questionnaire for
Medication (TSQM) prior to natalizumab initiation (BL) and after the 12th natali-
zumab infusion. Effectiveness, Convenience and Global Satisfaction subscale
scores range from 0 to 100; higher scores indicate higher satisfaction. ILOC was
assessed at BL and after the 12th infusion using the ILOC subscale of the Multidi-
mensional Health Locus of Control questionnaire. Subscale scores range from 6 to
36; higher scores indicate greater ILOC. Correlation analysis and regressionmodels
evaluated the relationship between ILOC and satisfaction with natalizumab after
12 infusions, controlling for BL patient characteristics. RESULTS: A total of 333
patients (mean age 46.810.4 years and median of 9 years since MS diagnosis)
completed all assessments. BL and 12th ILOCwas correlatedwith BL and 12th Global
Satisfaction (r0.13, p0.0247 and r0.27, p0.0001, respectively) and Effective-
ness (r0.23, p0.0001 and r0.29, p0.0001, respectively); 12th ILOC was corre-
lated with 12th convenience (r0.12, p0.0373). Regression model results showed
that, after controlling for covariates, higher ILOC predicted greater global satisfac-
tion (p0.003), effectiveness (p0.001) and convenience (p0.017) with natali-
zumab after 12 infusions. CONCLUSIONS: Patients with MS with stronger internal
beliefs about having control over their own health have higher satisfaction with
natalizumab treatment after 12 infusions. Interventions supporting and reinforc-
ing patients’ health beliefs may have a positive impact on overall treatment satis-
faction resulting in improved treatment adherence.
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OBJECTIVES: The Short Parkinson’s Evaluation Scale/Scales for Outcomes in Par-
kinson’s disease (SPES/SCOPA) was developed as a reliable and valid scale to eval-
uate motor impairment in Parkinson’s disease (PD) patients and can be completed
in less time than the gold standard Unified Parkinson’s Disease Rating Scale (UP-
DRS). This study aimed to further investigate the reliability and validity of the
SPES/SCOPA motor clinical examination, as relatively little research in the US has
done so.METHODS: The BRAVURA study was designed to investigate order effects
associated with the UPDRS motor examination at 2 centers in the US. Patients,
stratified by center and previous Hoehn and Yahr (H&Y) stage, were randomly
assigned to 1 of 2 UPDRS item sequences. All scale evaluations occurred during a
single clinic visit. In addition to the 8-item SPES/SCOPAmotor clinical examination
and the 14-itemUPDRSmotor examination, scales included current H&Y stage and
patient- and physician-rated Schwab and England Activities of Daily Living (ADL).
Datawere analyzed using Cronbach’s alpha and Spearman’s correlation. RESULTS:
Complete data were available for 112 patients (mean time from diagnosis  6.4
years). Relationships among the scales were comparable across the 2 experimental
groups, thus data were pooled for these analyses; SPES/SCOPA mean score  9.5
(SD  5.2). The SPES/SCOPA demonstrated good internal reliability (alpha  0.79).
Construct validity was supported with the SPES/SCOPA correlating 0.76 with the
UPDRS. Furthermore, the SPES/SCOPA correlated 0.47 with current H&Y stage and
0.39, 0.45 with patient- and physician-rated ADL, respectively. CONCLUSIONS:
In this US sample of PD patients with varied disease severity, the SPES/SCOPA
exhibited good psychometrics, including evidence of construct validity with the
current standard of motor impairment measurement. The SPES/SCOPA also had
good internal consistency and correlated with 3 broad evaluations of disease dis-
ability in a similar fashion to the UPDRS.
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